secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001935979-24-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven reports Q4 net loss $144.8M, cash $385.5M; key pipeline data milestones in 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $144.8M ($1.81/sh); non-GAAP adj net loss $128.9M ($1.61/sh).
- Cash, equivalents & securities $385.5M as of Dec 31, 2023 (incl. $3.7M restricted).
- Public offering closed Oct 2023: 11.76M shares at $22, net proceeds ~$242.4M.
- BHV-1300 Phase 1 IgG lowering data expected late Q1/early Q2 2024.
- Troriluzole Phase 3 OCD interim analysis topline results expected Q2 2024; taldefgrobep SMA data H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/0001935979-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/bhvn-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001935979-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer